CSF2 and neoplasm: However, recent studies have demonstrated that combination therapy with fractionated RT and CTLA-4 blockade (ipilimumab) or GM-CSF treatment, the percentage of patients showing abscopal tumour regression increased up to 20% [10, 13, 27].